Kymera TherapeuticsKYMR
About: Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Employees: 184
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
90% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 20
61% more capital invested
Capital invested by funds: $2.03B [Q2] → $3.26B (+$1.23B) [Q3]
12% more funds holding
Funds holding: 156 [Q2] → 174 (+18) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 7 [Q2] → 7 (+0) [Q3]
2.69% less ownership
Funds ownership: 110.82% [Q2] → 108.13% (-2.69%) [Q3]
11% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 62
27% less call options, than puts
Call options by funds: $2.82M | Put options by funds: $3.88M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Morgan Stanley James Quigley 0 / 0 met price target | 17%upside $49 | Equal-Weight Maintained | 6 Nov 2024 |
UBS Eliana Merle 56% 1-year accuracy 9 / 16 met price target | 76%upside $74 | Buy Maintained | 4 Nov 2024 |
Guggenheim | 24%upside $52 | Buy Maintained | 1 Nov 2024 |
Truist Securities Srikripa Devarakonda 54% 1-year accuracy 15 / 28 met price target | 26%upside $53 | Buy Reiterated | 1 Nov 2024 |
Oppenheimer Jeff Jones 38% 1-year accuracy 14 / 37 met price target | 33%upside $56 | Outperform Maintained | 27 Sept 2024 |
Financial journalist opinion
Based on 9 articles about KYMR published over the past 30 days
